A drug safety evaluation of rituximab and risk of hepatitis B

Bibliography

• Cerny T, Borisch B, Introna M, et al. Mechanism of action of rituximab. Anticancer Drugs 2002;13(Suppl 2):S3-10
   PubMed Web of Science ®Google Scholar
• Coiffier B, Feugier P, Mounier N, et al. Long-term results of the GELA study comparing R-CHOP and CHOP chemotherapy in older patients with diffuse large B-cell lymphoma show good survival in poor-risk patients [abstract 8009]. J Clin Oncol 2007;25(Suppl 18S):443s
   Google Scholar
• Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379-91
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725-32
   PubMed Web of Science ®Google Scholar
• Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121-7
   PubMed Web of Science ®Google Scholar
• Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood 1997;90:2188-95
   PubMed Web of Science ®Google Scholar
• Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81
   PubMed Web of Science ®Google Scholar
• Walsh M, Jayne D. Rituximab in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis and systemic lupus erythematosus: past, present and future. Kidney Int 2007;72:676-82
   PubMed Web of Science ®Google Scholar
• Bar-Or A, Calabresi PA, Arnold D, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72 week, open-label, phase I trial. Ann Neurol 2008;63:395-400
   PubMed Web of Science ®Google Scholar
• Monson NL, Cravens PD, Frohman EM, et al. Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch Neurol 2005;62:258-64
   PubMed Web of Science ®Google Scholar
• Godeau B, Porcher R, Fain O, et al. Rituximab safety and efficacy in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood 2008;112:999-1004
   PubMed Web of Science ®Google Scholar
• Dupuy A, Viguier M, Bedane C, et al. Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody). Arch Dermatol 2004;140:91-6
   PubMed Web of Science ®Google Scholar
• Goh MS, McCormack C, Dinh HV, et al. Rituximab in the adjuvant treatment of pemphigus vulgaris: a prospective open-label pilot study in five patients. Br J Dermatol 2007;156:990-6
   PubMed Web of Science ®Google Scholar
• Uthman I, Taher A, Abbas O, et al. Successful treatment of refractory skin manifestations of systemic lupus erythematosus with rituximab: report of a case. Dermatology 2008;216:257-9
   PubMed Web of Science ®Google Scholar
• Simon D, Hosli S, Kostylina G, et al. Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol 2008;121:122-8
   PubMed Web of Science ®Google Scholar
• Rituximab Package Insert. Biogen Idec, Inc. and Genentech, Inc., South San Francisco, CA; 2013
   Google Scholar
• McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-33
   PubMed Web of Science ®Google Scholar
• Aksoy S, Harputluoglu H, Kilickap S, et al. Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma 2007;48:1307-12
   PubMed Web of Science ®Google Scholar
• Ofatumumab Package Insert. GlaxoSmithKline; Research Triangle Park, NC; 2013
   Google Scholar
• Obinutuzumab Package Insert. Genentech, San Francisco, CA; 2013
   Google Scholar
• Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008;359:1486-500
   PubMed Web of Science ®Google Scholar
• Ganem D, Prince AM. Hepatitis B infection--natural history and clinical consequences. N Engl J Med 2004;350:1118-29
   PubMed Web of Science ®Google Scholar
• WHO. Hepatitis B: fact sheet. no. 204. 2013. Available from: www.who.int/mediacentre/factsheets/fs204/en/
   Google Scholar
• Hoofnagle JH. Serologic markers of hepatitis B virus infection. Ann Rev Med 1981;32:1-11
   PubMed Web of Science ®Google Scholar
• Rehermann B, Ferrari C, Pasquinelli C, et al. The hepatitis B virus persists for decades after patients’ recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996;2:1104-8
   PubMed Web of Science ®Google Scholar
• Leung NW, Tam JS, Lau GT, et al. Hepatitis B virus DNA in peripheral blood leukocytes. A comparison between hepatocellular carcinoma and other hepatitis B virus-related chronic liver diseases. Cancer 1994;73:1143-8
   PubMed Web of Science ®Google Scholar
• Matsui T, Kang JH, Nojima M, et al. Reactivation of hepatitis B virus in patients with undetectable HBsAg undergoing chemotherapy for malignant lymphoma or multiple myeloma. J Med Virol 2013;85:1900-6
   PubMed Web of Science ®Google Scholar
• Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004;126:1750-8
   PubMed Web of Science ®Google Scholar
• Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-2
   PubMed Web of Science ®Google Scholar
• Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006;43:209-20
   PubMed Web of Science ®Google Scholar
• Hwang JP, Vierling JM, Zelenetz AD, et al. Hepatitis B virus management to prevent reactivation after chemotherapy: a review. Support Care Cancer 2012;20:2999-3008
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH, Dusheiko GM, Schafer DF, et al. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 1982;96:447-9
   PubMed Web of Science ®Google Scholar
• Yeo W, Chan PK, Hui P, et al. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol 2003;70:553-61
   PubMed Web of Science ®Google Scholar
• Nagamatsu H, Kumashiro R, Itano S, et al. Investigation of associating factors in exacerbation of liver damage after chemotherapy in patients with HBV-related HCC. Hepatol Res 2003;26:293-301
   PubMed Web of Science ®Google Scholar
• Jang JW, Choi JY, Bae SH, et al. Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma. J Hepatol 2004;41:427-35
   PubMed Web of Science ®Google Scholar
• Eren OO, Artac M, Boruban MC, et al. Chemotherapy-induced hepatitis B virus reactivation in HbsAg positive cancer patients: a single center experience. Med Oncol 2009;26:386-92
   PubMed Web of Science ®Google Scholar
• Cheng JC, Liu MC, Tsai SY, et al. Unexpectedly frequent hepatitis B reactivation by chemoradiation in postgastrectomy patients. Cancer 2004;101:2126-33
   PubMed Web of Science ®Google Scholar
• Wang YD, Cui GH, Li M, et al. Hepatitis B virus reactivation in a chronic myeloid leukemia patient treated with imatinib mesylate. Chin Med J (Engl) 2012;125:2636-7
   PubMed Web of Science ®Google Scholar
• Ohno M, Narita Y, Miyakita Y, et al. Reactivation of hepatitis B virus after glioblastoma treatment with temozolomide—case report. Neurol Med Chir (Toyko) 2011;51:728-31
   PubMed Web of Science ®Google Scholar
• Lau GK, Leung YH, Fong DY, et al. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood 2002;99:2324-30
   PubMed Web of Science ®Google Scholar
• Lok AS, Liang RH, Chiu EK, et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991;100:182-8
   PubMed Web of Science ®Google Scholar
• Loomba R, Rowley A, Wesley R, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008;148:519-28
   PubMed Web of Science ®Google Scholar
• Pei SN, Chen CH, Lee CM, et al. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol 2010;89:255-62
   PubMed Web of Science ®Google Scholar
• Yeo W, Chan PK, Zhong S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000;62:299-307
   PubMed Web of Science ®Google Scholar
• Yeo W, Zee B, Zhong S, et al. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004;90:1306-11
   PubMed Web of Science ®Google Scholar
• Liang R. How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood 2009;113:3147-53
   PubMed Web of Science ®Google Scholar
• Yeo W, Chan HL. Hepatitis B virus reactivation associated with anti-neoplastic therapy. J Gastroenterol Hepatol 2013;28:31-7
   PubMed Web of Science ®Google Scholar
• Zelenetz AD, Wierda WG, Abramson JS, et al. Non-Hodgkin’s lymphomas, version 1.2013. J Nat Compr Canc Netw 2013;11:257-72
   PubMed Web of Science ®Google Scholar
• Cheng AL, Hsiung CA, Su IJ, et al. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 2003;37:1320-8
   PubMed Web of Science ®Google Scholar
• Tur-Kaspa R, Burk RD, Shaul Y, et al. Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc Natl Acad Sci USA 1986;83:1627-31
   PubMed Web of Science ®Google Scholar
• Yang SH, Kuo SH. Reactivation of hepatitis B virus during rituximab treatment of a patient with follicular lymphoma. Ann Hematol 2008;87:325-7
   PubMed Web of Science ®Google Scholar
• Tsutsumi Y, Shigematsu A, Hashino S, et al. Analysis of reactivation of hepatitis B virus in the treatment of B cell non-Hodgkin’s lymphoma in Hokkaido. Ann Hematol 2009;88:375-7
   PubMed Web of Science ®Google Scholar
• Pyrpasopoulou A, Douma S, Vassiliadis T, et al. Reactivation of chronic hepatitis B virus infection following rituximab administration for rheumatoid arthritis. Rheumatol Int 2011;31:403-4
   PubMed Web of Science ®Google Scholar
• Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001;344:68-9
   PubMed Web of Science ®Google Scholar
• Westhoff TH, Jochimsen F, Schmittel A, et al. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 2003;102:1930
   PubMed Web of Science ®Google Scholar
• Soong YL, Lee KM, Lui HF, et al. Hepatitis B reactivation in a patient receiving radiolabeled rituximab. Ann Hematol 2005;84:61-2
   PubMed Web of Science ®Google Scholar
• Sarrecchia C, Cappelli A, Aiello P. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. J Infect Chemother 2005;11:189-91
   PubMedGoogle Scholar
• Umemura T, Kiyosawa K. Fatal HBV reactivation in a subject with anti-HBs and anti-HBc. Intern Med 2006;45:747-8
   PubMed Web of Science ®Google Scholar
• Sera T, Hiasa Y, Michitaka K, et al. Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. Intern Med 2006;45:721-4
   PubMed Web of Science ®Google Scholar
• Yeo W, Chan TC, Leung NW, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009;27:605-11
   PubMed Web of Science ®Google Scholar
• Hui CK, Cheung WW, Zhang HY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006;131:59-68
   PubMed Web of Science ®Google Scholar
• Evens AM, Jovanovic BD, Su YC, et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol 2011;22:1170-80
   PubMed Web of Science ®Google Scholar
• Dong HJ, Ni LN, Sheng GF, et al. Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy: a meta-analysis. J Clin Virol 2013;57:209-14
   PubMed Web of Science ®Google Scholar
• Huang YH, Hsiao LT, Hong YC, et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol 2013;31:2765-72
   PubMed Web of Science ®Google Scholar
• Borentain P, Colson P, Coso D, et al. Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer. J Viral Hepat 2010;17:807-15
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Motokura T, Fujita A, et al. Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan 1987-1991. Cancer 1996;78:2210-15
   PubMed Web of Science ®Google Scholar
• Lau GK. Hepatitis B reactivation after chemotherapy: two decades of clinical research. Hepatol Int 2008;2:152-62
   PubMed Web of Science ®Google Scholar
• Lazdina U, Alheim M, Nystrom J, et al. Priming of cytotoxic T cell responses to exogenous hepatitis B virus core antigen is B cell dependent. J Gen Virol 2003;84:139-46
   PubMed Web of Science ®Google Scholar
• Lau GK, Yiu HH, Fong DY, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003;125:1742-9
   PubMed Web of Science ®Google Scholar
• Perceau G, Diris N, Estines O, et al. Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma. Br J Dermatol 2006;155:1053-6
   PubMed Web of Science ®Google Scholar
• Ceccarelli L, Salpini R, Sarmati L, et al. Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy. J Infect 2012;65:180-3
   PubMed Web of Science ®Google Scholar
• Chew E, Thursky K, Seymour JF. Very late onset hepatitis-B virus reactivation following rituximab despite lamivudine prophylaxis: the need for continued vigilance. Leuk Lymphoma 2014;55(4):938-9
   PubMed Web of Science ®Google Scholar
• Firpi RJ, Nelson DR. Viral hepatitis: manifestations and management strategy. Hematology Am Soc Hematol Educ Program (2006) 2006;375-80
   Google Scholar
• Hirakawa T, Yamaguchi H, Yokose N, et al. Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma. Ann Hematol 2010;89:897-904
   PubMed Web of Science ®Google Scholar
• Lalazar G, Rund D, Shouval D, et al. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 2007;136:699-712
   PubMed Web of Science ®Google Scholar
• Markovic S, Drozina G, Vovk M, et al. Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. Hepatogastroenterology 1999;46:2925-30
   PubMed Web of Science ®Google Scholar
• Liao CA, Lee CM, Wu HC, et al. Lamivudine for the treatment of hepatitis B virus reactivation following chemotherapy for non-Hodgkin’s lymphoma. Br J Haematol 2002;116:166-9
   PubMed Web of Science ®Google Scholar
• Yeo W, Chan PK, Ho WM, et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004;22:927-34
   PubMed Web of Science ®Google Scholar
• Ikeda M. Reactivation of hepatitis B virus in patients receiving chemotherapy. Jpn J Clin Oncol 2013;43:8-16
   PubMed Web of Science ®Google Scholar
• Hsu C, Tsou HH, Lin SJ, et al. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology 2013. [ Epub ahead of print]
   Google Scholar
• Kusumoto S, Tanaka Y, Suzuki R, et al. Prospective nationwide observational study of hepatitis B virus (HBV) DNA monitoring and preemptive antiviral therapy for HBV reaction in patients with B-cell non-Hodgkin lymphoma following rituximab containing chemotherapy: results of interim analysis. Blood 2012;120:abstract 2641
   Google Scholar
• Lamivudine Package Insert. GlaxoSmith-Kline; Research Triangle Park, NC; 2004
   Google Scholar
• Hann HW, Gregory VL, Dixon JS, et al. A review of the one-year incidence of resistance to lamivudine in the treatment of chronic hepatitis B: lamivudine resistance. Hepatol Int 2008;2:440-56
   PubMed Web of Science ®Google Scholar
• Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-20
   PubMed Web of Science ®Google Scholar
• Gish RG, Lok AS, Chang TT, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007;133:1437-44
   PubMed Web of Science ®Google Scholar
• Li HR, Huang JJ, Guo HQ, et al. Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy. J Viral Hepat 2011;18:877-83
   PubMed Web of Science ®Google Scholar
• Garg H, Sarin SK, Kumar M, et al. Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. Hepatology 2011;53:774-80
   PubMed Web of Science ®Google Scholar
• European Association For The Study of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J hepatol 2009;50:227-42
   PubMed Web of Science ®Google Scholar
• Hui CK, Cheung WW, Au WY, et al. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut 2005;54:1597-603
   PubMed Web of Science ®Google Scholar
• Weinbaum CM, Williams I, Mast EE, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 2008;57:1-20
   PubMedGoogle Scholar
• Artz AS, Somerfield MR, Feld JJ, et al. American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol 2010;28:3199-202
   PubMed Web of Science ®Google Scholar
• Day FL, Karnon J, Rischin D. Cost-effectiveness of universal hepatitis B virus screening in patients beginning chemotherapy for solid tumors. J Clin Oncol 2010;29:3270-7
   Web of Science ®Google Scholar
• Zurawska U, Hicks LK, Woo G, et al. Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis. J Clin Oncol 2012;30:3167-73
   PubMed Web of Science ®Google Scholar
• Maddrey WC, Hepatitis B. An important public health issue. J Med Virol 2000;61:362-6
   PubMed Web of Science ®Google Scholar
• Abe A, Inoue K, Tanaka T, et al. Quantitation of Hepatitis B Virus Genomic DNA by Real-Time Detection PCR. J Clin Microbiol 1999;37:2899-903
   PubMed Web of Science ®Google Scholar
• Mitka M. FDA: increased HBV reactivation risk with ofatumumab or rituximab. JAMA 2013;310:1664-4
   PubMed Web of Science ®Google Scholar
• Chang T-T, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-10
   PubMed Web of Science ®Google Scholar
• Yuan Y, Iloeje UH, Hay J, et al. Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients. J Manag Care Pharm 2008;14:21-33
   PubMed Web of Science ®Google Scholar
• Ziakas PD, Karsaliakos P, Mylonakis E. Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance. Haematologica 2009;94:998-1005
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002;346:235-42
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008;26:4579-86
   PubMed Web of Science ®Google Scholar
• Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomized controlled trial. Lancet 2011;377:42-51
   PubMed Web of Science ®Google Scholar
• Targhetta C, Cabras MG, Mamusa AM, et al. Hepatitis B virus-related liver disease in isolated anti-hepatitis B-core positive lymphoma patients receiving chemo- or chemo-immune therapy. Haematologica 2008;93:951-2
   PubMed Web of Science ®Google Scholar
• Wang F, Xu RH, Luo HY, et al. Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma. BMC Cancer 2008;8:115
   PubMed Web of Science ®Google Scholar
• Fukushima N, Mizuta T, Tanaka M, et al. Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier. Ann Oncol 2009;20:2013-17
   PubMed Web of Science ®Google Scholar
• Ji D, Cao J, Hong X, et al. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/HBcAb-positive: a multicenter retrospective study. Eur J Haematol 2010;85:243-50
   PubMed Web of Science ®Google Scholar
• Koo YX, Tan DS, Tan IB, et al. Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy. Cancer 2010;116:115-21
   PubMed Web of Science ®Google Scholar
• Koo YX, Tay M, Teh YE, et al. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis. Ann Hematol 2011;90:1219-23
   PubMed Web of Science ®Google Scholar
• Persico M, De Marino F, Russo GD, et al. Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma. Blood 2002;99:724-5
   PubMed Web of Science ®Google Scholar
• Lee GW, Ryu MH, Lee JL, et al. The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBsAg)-positive patients with Non-Hodgkin’s lymphoma who receive cytotoxic chemotherapy. J Korean Med Sci 2003;18:849-54
   PubMed Web of Science ®Google Scholar
• Leaw SJ, Yen CJ, Huang WT, et al. Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. Ann Hematol 2004;83:270-5
   PubMed Web of Science ®Google Scholar
• Ozguroglu M, Bilici A, Turna H, et al. Reactivation of hepatitis B virus infection with cytotoxic therapy in non-Hodgkin’s lymphoma. Med Oncol 2004;21:67-72
   PubMed Web of Science ®Google Scholar
• Vassiliadis T, Garipidou V, Tziomalos K, et al. Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy—a prospective case series. Am J Hematol 2005;80:197-203
   PubMed Web of Science ®Google Scholar
• He YF, Li YH, Wang FH, et al. The effectiveness of lamivudine in preventing hepatitis B viral reactivation in rituximab-containing regimen for lymphoma. Ann Hematol 2008;87:481-5
   PubMed Web of Science ®Google Scholar
• Hsu C, Hsiung CA, Su IJ, et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin’s lymphoma: a randomized trial. Hepatology 2008;47:844-53
   PubMed Web of Science ®Google Scholar
• Kim SJ, Hsu C, Song YQ, et al. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group. Eur J Cancer 2013;49:3486-96
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. FDA Drug Safety Communication: Boxed warning and new recommendations to decrease risk of hepatitis B reactivation with the immune-suppressing and anti-cancer drugs Arzerra (ofatumumab) and rituxan (rituximab). 2013. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm366406.htm
   Google Scholar